Summary
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
History
ADC Therapeutics was founded in 2014 and has been advancing a unique approach to ADC research and development, which holds promise for creating next-generation targeted systemic therapies for certain aggressive and hard-to-treat cancers.
Mission
Our mission is to develop and deliver novel and innovative therapies that capitalize on the power of combination and targeted therapies for cancer patients with unmet medical needs.
Vision
Our vision is to be a leader in developing and supplying critical therapies for patients with cancer worldwide.
Key Team
Mr. Peter J. Graham Esq. (Chief Legal Officer)
Ms. Kimberly Pope (Sr. VP & Chief People Officer)
Dr. Patrick van Berkel Ph.D. (Chief Scientific Officer)
Amanda Hamilton (Investor Relations Officer)
Ms. Susan Romanus (Chief Compliance & Quality Officer)
Dr. Joseph Camardo Ph.D. (Chief Medical Officer)
Mr. David M. Gilman (Chief Bus. & Strategy Officer)
Recognition and Awards
ADC Therapeutics has been recognized with several awards over the years, including the Prix Galien from Switzerland, Roche Prize, and the prestigious Prix Galien from France, among others.
References
Switzerland 